...C.R. Chapple; L. Baert; P. Thind; K. Höfner; G.S.S. Khoe; A. Spångberg Objectives: To compare the safety and tolerability of tamsulosin 0.4 mg once daily in younger (<65 years) and older (≥65 years) patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO...

... cardiovascular untoward effects, eventually leading to premature treatment discontinuation. Alfuzosin (although primarily developed as an anti-hypertensive agent) and tamsulosin in contrast, are better tolerated; the former nevertheless carries a more distinct risk of symptomatic impairment of blood pressure...

... of transurethral vaporisation of the prostate has increased to 62% of urologists. For those patients being treated with medication, 36% are treated with terazosin, 31% with doxazosin, 15% with finasteride and 18% with tamsulosin, which was introduced only recently and is growing. Conclusions: In the future...

... safety-relevant, physiological blood pressure control in normotensives with LUTS than tamsulosin, which does not reduce elevated blood pressure in comparison with placebo and has little effect on orthostatic blood pressure control. However, clinical selectivity and cardiovascular safety are also defined...

...K. Höfner; H. Claes; T.M. De Reijke; B. Folkestad; M.J. Speakman Objective: To evaluate the effect of tamsulosin, 0.4 mg once daily, on sexual function in comparison with placebo and alfuzosin, 2.5 mg three times daily, in patients with lower urinary tract symptoms (LUTS) suggestive of benign...

...Michael G. Wyllie Objective: The recent publication of multicentre US studies raises the possibility that the response to tamsulosin is dose-related and less than maximum at 0.4 mg. The objective of the present study was to calculate pharmacologically equivalent, alpha-blocking doses of doxazosin...

...Bob Djavan; Michael Marberger Objective: To assess whether the α 1 -adrenoceptor antagonists currently available for the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) (alfuzosin, terazosin, doxazosin and tamsulosin) can be distinguished...

... with LUTS by impairing physiological blood pressure (BP) control, even when their effect on unchallenged BP may be quite low. Preclinically, tamsulosin, a sulphonamide-substituted phenethylamine, has a relative selectivity for the α 1 -adrenoceptors of the lower urinary tract. Clinically, this is associated...

...Martin C. Michel; Hans-Ulrich Bressel; Ludwig Mehlburger; Mark Goepel Objective: To compare the efficacy, global tolerability and blood pressure effects of tamsulosin (0.4 mg once daily) in subgroups of patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction...

...C. de Mey; M.C. Michel; J. McEwen; T. Moreland Objectives: This single-centre, double-blind, randomized parallel-group study compared ambulatory blood pressure (AMBP) and heart rate (HR) profiles and responses to orthostatic testing (OT) for recommended regimens of tamsulosin (TAM, modified release...

...C.C. Schulman; J. Cortvriend; U. Jonas; T.M.T.W. Lock; S. Vaage; M.J. Speakman Objective: This open-label extension study evaluated the efficacy and safety of tamsulosin (0.4 mg as a modified release formulation) once daily in patients with benign prostatic enlargement, lower urinary tract symptoms...

...C.R. Chapple; J.J. Wyndaele; J. Nordling; F. Boeminghaus; A.F.G.V.M. Ypma; P. Abrams Objective: This meta-analysis of two European studies evaluated the efficacy and safety of modified-release tamsulosin 0.4 mg once daily compared with placebo in patients with benign prostatic enlargement, lower...